Dr. Powles on the Impact of Immunotherapy in Kidney Cancer

Thomas Powles, MD
Published: Sunday, Nov 19, 2017



Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

There has been an enormous change in the treatment of kidney cancer in 2017 with studies of immunotherapy in the frontline setting, says Powles.

CheckMate-214 is the study credited with potentially changing the frontline treatment of this disease, demonstrating a reduced risk of death of 32% with the combination on nivolumab (Opdivo) and ipilimumab (Yervoy) compared with sunitinib (Sutent).
 


Thomas Powles, MD, Barts Cancer Institute, discusses the impact of immunotherapy on the treatment landscape of kidney cancer.

There has been an enormous change in the treatment of kidney cancer in 2017 with studies of immunotherapy in the frontline setting, says Powles.

CheckMate-214 is the study credited with potentially changing the frontline treatment of this disease, demonstrating a reduced risk of death of 32% with the combination on nivolumab (Opdivo) and ipilimumab (Yervoy) compared with sunitinib (Sutent).
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x